The sensitization we found to Dasatinib by ABT-737 suggests that Dasatinib as a metabolic stressor not only affects glycolysis it may also affect FAO metabolism and open a therapeutic window where a Bcl2 inhibitor could be efficient to promote apoptosis in CLL (Supplementary FIGURE 2). The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.